Abbott Makes First Xience Submission To FDA As Guidant Biz Boosts Sales
This article was originally published in The Gray Sheet
Executive Summary
Abbott kicked off the premarket approval submission process July 19 for the Xience everolimus-eluting coronary stent, taking a step closer to capitalizing on its recent acquisition of Guidant's vascular business